{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:08:29Z","timestamp":1738645709777,"version":"3.35.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.transci.2024.104057","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:18:40Z","timestamp":1734398320000},"page":"104057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?"],"prefix":"10.1016","volume":"64","author":[{"given":"Tugce Nur","family":"Yigenoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simten","family":"Dagdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar Uncu","family":"Ulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Kuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Durdu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sezgin","family":"Pepeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Kul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emin","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdal","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Ula\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.transci.2024.104057_bib1","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.transci.2024.104057_bib2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2009-12-258442","article-title":"The best endpoint for acute GVHD treatment trials","volume":"115","author":"MacMillan","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2024.104057_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/bbmt.2002.v8.pm11858189","article-title":"Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"10.1016\/j.transci.2024.104057_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bmt.1703032","article-title":"Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin","volume":"27","author":"Khoury","year":"2001","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2024.104057_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bmt.1705762","article-title":"Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease","volume":"40","author":"Perales","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2024.104057_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Soci\u00e9","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.transci.2024.104057_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bmt.2014.69","article-title":"Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation","volume":"49","author":"Castilla-Llorente","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.transci.2024.104057_bib8","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2006-08-013995","article-title":"A phase 2\/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease","volume":"109","author":"Macmillan","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.transci.2024.104057_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.rmed.2011.02.002","article-title":"The discovery of \u03b11-antitrypsin and its role in health and disease","volume":"105","author":"Janciauskiene","year":"2011","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.transci.2024.104057_bib10","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1074\/jbc.M607976200","article-title":"Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP","volume":"282","author":"Janciauskiene","year":"2007","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.transci.2024.104057_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1189\/jlb.0208145","article-title":"Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood","volume":"85","author":"Pott","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"42","key":"10.1016\/j.transci.2024.104057_bib12","doi-asserted-by":"crossref","first-page":"16236","DOI":"10.1073\/pnas.0807627105","article-title":"alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice","volume":"105","author":"Lewis","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"34","key":"10.1016\/j.transci.2024.104057_bib13","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.1073\/pnas.0505579102","article-title":"Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice","volume":"102","author":"Lewis","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.transci.2024.104057_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.1117665109","article-title":"Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation","volume":"109","author":"Tawara","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.transci.2024.104057_bib15","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1182\/blood-2011-07-365247","article-title":"Inhibition of IL-32 activation by \u03b1-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model","volume":"118","author":"Marcondes","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.transci.2024.104057_bib16","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2011-07-368720","article-title":"Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation","volume":"120","author":"Brennan","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.transci.2024.104057_bib17","first-page":"939","article-title":"Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"90","author":"Lee","year":"2005","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.transci.2024.104057_bib18","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1182\/blood-2011-12-397968","article-title":"Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease","volume":"119","author":"Rodriguez-Otero","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2024.104057_bib19","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbmt.2016.05.011","article-title":"Response of Steroid-Refractory Acute GVHD to \u03b11-Antitrypsin","volume":"22","author":"Marcondes","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2024.104057_bib20","first-page":"17","article-title":"Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD","volume":"3","author":"Stocks","year":"2006"},{"issue":"9","key":"10.1016\/j.transci.2024.104057_bib21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/infdis\/jiu620","article-title":"Acute phase protein \u03b11-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses","volume":"211","author":"Kaner","year":"2015","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.transci.2024.104057_bib22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","article-title":"Graft-versus-host disease treatment: predictors of survival","volume":"16","author":"Levine","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104057_bib23","first-page":"S19eS481","article-title":"Alpha 1 anti-trypsin (AAT): novel strategy to treat steroid refractory acute graft versus host disease","author":"Goldstein","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"10.1016\/j.transci.2024.104057_bib24","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2017-11-815746","article-title":"\u03b11-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","volume":"131","author":"Magenau","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2024.104057_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V95.1.83","article-title":"Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease","volume":"95","author":"Przepiorka","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2024.104057_bib26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2004-01-0028","article-title":"Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2024.104057_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbmt.2004.11.022","article-title":"Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease","volume":"11","author":"Shaughnessy","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"10.1016\/j.transci.2024.104057_bib28","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood-2005-12-4851","article-title":"Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +\u20095 responders and no advantage for nonresponders receiving anti-thymocyte globulin","volume":"107","author":"Van Lint","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2024.104057_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajh.20752","article-title":"Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Busca","year":"2007","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.transci.2024.104057_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bbmt.2005.03.002","article-title":"A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease","volume":"11","author":"Carpenter","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.transci.2024.104057_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"10.1016\/j.transci.2024.104057_bib32","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.bbmt.2020.05.014","article-title":"Human-derived \u03b11-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease","volume":"26","author":"Giannoni","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2024.104057_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0016-5085(83)80074-2","article-title":"Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin","volume":"85","author":"Weisdorf","year":"1983","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.transci.2024.104057_bib34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1183\/09031936.98.11020428","article-title":"Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin","volume":"11","author":"Wencker","year":"1998","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.transci.2024.104057_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Soci\u00e9","year":"2017","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022400243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022400243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:48:29Z","timestamp":1738572509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305022400243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S147305022400243X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.104057","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.104057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104057"}}